Follow-up of clinical outcomes and medication use until 5 years for study population split for change in left ventricular ejection fraction between 4 months and 24 months
| LVEF improvement (n=78%) | LVEF deterioration (n=77%) | p Value | |
| Medication at 4 months | |||
| ACE-inhibitors/ATII antagonists | 72 (92) | 69 (90) | 0.32 |
| Beta-blockers | 72 (92) | 69 (90) | 0.56 |
| Medication at 2 years | |||
| ACE-inhibitors/ATII antagonists | 73 (94) | 67 (87) | 0.35 |
| Beta-blockers | 75 (96) | 61 (80) | 0.004 |
| NYHA class I | |||
| 4 months | 63 (81) | 66 (86) | 0.41 |
| 2 years | 64 (82) | 70 (92) | 0.06 |
| Hospitalisation for heart failure | |||
| 2 years | 1 (1) | 2 (3) | 0.56 |
| 5 years | 3 (4) | 1 (1) | 0.56 |
| Repeat PCI | |||
| 2 years | 17 (21) | 16 (21) | 0.88 |
| 5 years | 18 (23) | 18 (23) | 1.00 |
| CABG | |||
| 2 years | 0 (0) | 0 (0) | 1.00 |
| Recurrent myocardial infarction* | |||
| 5 years | 1 (1.3) | 3 (4) | 0.31 |
| Mortality* | |||
| 5 years | 3 (4) | 1 (1) | 0.31 |
*Patients who died (n=3) or suffered recurrent myocardial infarction (n=4) in the first 24 months after PCI were not included in this substudy.
AT, angiotensin; CABG, coronary artery bypass grafting; NYHA, New York Heart Association; PCI, percutaneous coronary intervention.